UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The Company has an innovative and broad pipeline of product candidates that it believes can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology.

We have several drugs in various stages of clinical investigation.  Our lead drug candidate uses our proprietary formulation of the chemotherapy drug mitomycin, which is a generic drug that is being administered off-label for urothelial cancer treatment.  The water-based formulation currently on the market is used as an adjuvant, post-surgery, therapy.

Our company’s research is focused, in part, on various potential uses of RTGel, our proprietary drug delivery technology.  Current areas of therapeutic focus are:  non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, or UTUC, and low-grade bladder cancer.  RTGel is a reverse thermally triggered hydrogel that may enable sustained release of an active drug in various types of urothelial cancer.  Our preliminary research suggests that the gel does not interfere with the natural flow of fluids in the urinary tract and can be absorbed into the body over time. We are encouraged by our preliminary research that suggests that RTGel may help to increase the dwell time, as well as the tissue coverage throughout the organ, with the active drug.  We are committed to continued research and development in our quest to develop new medicines that may offer patients safe and effective alternatives to surgery.

The Company’s clinical stage pipeline also includes a proprietary immunotherapy product candidate for the treatment of carcinoma in situ of the bladder using a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7, or TLR7, agonist.

In addition, we have licensed worldwide rights for use of RTGel with onabotulinumtoxin A for patients suffering from overactive bladder.